Banks dive into biotech as first IPO wave hits HK

The Hong Kong Stock Exchange’s revolutionary change to its listing regime for biotechnology companies is starting to pay off, as the pipeline of pre-revenue firms looking to go public builds. But there are numerous challenges ahead, not least in understanding the sector and the risks involved. Jonathan Breen reports.